New hope for lupus skin flares: experimental drug VENT-03 enters Mid-Stage trial
Disease control
Recruiting now
This study tests whether an experimental drug called VENT-03 can reduce skin symptoms in people with cutaneous lupus (CLE), with or without systemic lupus (SLE). About 24 adults will receive either VENT-03 or a placebo for 4 weeks, then all will receive VENT-03 for 8 more weeks. …
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC